MelioOne®
The first non-contraceptive
IUD designed for Period Pain
Period pain needs innovation
1.8 billion people menstruate every month
1.4 billion experience pain with their periods
38% of menstruating women report pain so severe that it disrupts activities of daily life
Meliodays is a pharmaceutical company developing a first-in-class intrauterine device with the potential to transform how period pain can be managed. Our prototype is currently advancing with nonclinical development.
No hormones.
No cycle disruption.
Reduced systemic exposure.
MelioOne® is being developed as the first non-hormonal, non-contraceptive intrauterine device for period pain. It uses a slow-release mechanism to deliver a low, sustained dose of an established pain medicine locally over two years, approximately equivalent to one 400 mg tablet, spread out gradually to reduce systemic exposure.
MelioOne® is classified as a combination product: a medical device paired with a pharmacological agent. This dual classification means our product advancement follows stringent regulatory frameworks, an approach designed to build the foundations for trust and long-term safety as development progresses.
The gender health gap is real, and period pain shows it most clearly. Despite affecting up to 91% of women worldwide, dysmenorrhoea remains underdiagnosed, undertreated, and widely normalized. Menstrual health is still one of the least prioritised and underfunded areas of research, with neglect carrying personal, economic, and social costs, from missed education to reduced workplace participation. We believe normalizing pain has gone on long enough. Women deserve better, and our work begins with menstruation, but it doesn’t end there.
Latest News, Product Developments and Corporate Updates
29.07.202520.03.2025